Undisclosed SIK2 inhibitor / Nimbus Therap - LARVOL DELTA

Selective SIK2 inhibition suppresses inflammation and disease in mouse and human models of rheumatoid arthritis (ACR Convergence 2026) - No abstract available

Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Selective SIK2 Inhibitors Suppress Proinflammatory Responses while Upregulating Pro-Resolution Signals in Stimulated Myeloid Cells and Mice (IMMUNOLOGY 2026) - "Selective targeting of SIK2 in myeloid cells has the potential to suppress inflammation and promote tissue healing, offering a novel oral therapeutic approach for more complete disease control in autoimmune and inflammatory diseases."

IO biomarker • Preclinical • Immunology • Inflammation • IL10 • JAK1 • SIK1

Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026 (Businesswire) - "Preclinical data demonstrate that selective inhibition of SIK2 drives a dual pharmacological profile in myeloid cells and mice, suppressing proinflammatory cytokines while simultaneously promoting pro-resolution and tissue repair signals, a mechanistic profile distinct from SIK3 and JAK1 inhibition."

Preclinical • Immunology • Inflammation

Selective SIK2 inhibition suppresses intestinal inflammation and promotes mucosal healing in models of colitis (ECCO-IBD 2026) - "Moreover, transcriptome analysis of colon tissue samples from SIK2-inhibitor treated mice confirmed the attenuation of intestinal inflammation and upregulation of mucosal healing pathways by selective SIK2 inhibition. Conclusion Our first-in-class highly selective small molecule SIK2 kinase inhibitors represent a unique mechanism of downregulating intestinal inflammation and upregulating mucosal healing, offering a novel oral therapeutic approach for IBD."

IO biomarker • Immunology • Inflammation • Inflammatory Bowel Disease • IL10 • IL12A • IL1B • IL1R1 • IL6 • LCN2 • MUC2 • OCLN • SIK1 • TJP1 • TNFA

Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO) (Businesswire) - "'We look forward to advancing our novel SIK2 program toward first-in-human studies for inflammatory and autoimmune diseases in the months ahead.'"

First-in-human • New trial • Preclinical • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis